The Use of Hyalomatrix$^{(R)}$ in the Treatment of Difficult To Heal Wound

치료하기 어려운 창상에서 하이알로매트릭스$^{(R)}$의 사용

  • Koo, Hyun-Kook (Institute for Human Tissue Restoration, Department of Plastic and Reconstructive Surgery, Yonsei University College of Medicine) ;
  • Kim, Young-Seok (Institute for Human Tissue Restoration, Department of Plastic and Reconstructive Surgery, Yonsei University College of Medicine) ;
  • Hong, Jong-Won (Institute for Human Tissue Restoration, Department of Plastic and Reconstructive Surgery, Yonsei University College of Medicine) ;
  • Roh, Tai-Suk (Institute for Human Tissue Restoration, Department of Plastic and Reconstructive Surgery, Yonsei University College of Medicine) ;
  • Rah, Dong-Kwun (Institute for Human Tissue Restoration, Department of Plastic and Reconstructive Surgery, Yonsei University College of Medicine)
  • 구현국 (연세대학교 의과대학 인체조직복원연구소, 성형외과학교실) ;
  • 김영석 (연세대학교 의과대학 인체조직복원연구소, 성형외과학교실) ;
  • 홍종원 (연세대학교 의과대학 인체조직복원연구소, 성형외과학교실) ;
  • 노태석 (연세대학교 의과대학 인체조직복원연구소, 성형외과학교실) ;
  • 나동균 (연세대학교 의과대학 인체조직복원연구소, 성형외과학교실)
  • Received : 2010.04.29
  • Accepted : 2010.07.19
  • Published : 2010.09.10

Abstract

Purpose: Although traditional and current treatment strategies may demonstrate success, persistence or recurrence of difficult-to-heal wounds remain significant problems. A novel product, Hyalomatrix$^{(R)}$ (Fidia Advanced Biopolymer, Abano Terme, Italy) is a bilayer of an benzyl esterified hyaluronan scaffold beneath a silicone membrane. The scaffold delivers hyaluronan to the wound, and the silicone membrane acts as a temporary epidermal barrier. We present the results obtained with Hyalomatrix$^{(R)}$ in the treatment of difficult-to-heal wounds. Methods: From November, 2008 to March, 2010, Hyalomatrix$^{(R)}$ has been used on total 10 patients with wounds that were expected difficult to heal with traditional and other current strategies. After average 37.4 days from development of wounds, Hyalomatrix$^{(R)}$ was applied after wound debridement. On the average, Hyalomatrix$^{(R)}$ application period was 17.6 days. After average 16.5 days from removal of Hyalomatrix$^{(R)}$, skin grafts was performed. Results: In all cases, regeneration of fibrous granulation tissues and edge re-epithelization were present after the application of the Hyalomatrix$^{(R)}$. And all of the previous inflammatory signs were reduced. After skin grafts, no adverse reactions were recorded in 9 cases. But in one case, postoperative wound infection occured due to a lack of efficient fibrous tissues. In this model, the Hyalomatrix$^{(R)}$ acts as a hyaluronan delivery system and a barrier from the external environments. In tissue repair processes, the hyaluronan performs to facilitate the entry of a large number of cells into the wounds, to orientate the deposition of extracellular matrix fibrous components and to change the microenvironment of difficult-to-heal wounds. Conclusion: Our study suggests that Hyalomatrix$^{(R)}$ could be a good and feasible approach for difficult-to-heal wounds. The Hyalomatrix$^{(R)}$ improves microenvironments of difficult-to-heal wounds, reduces infection rates and physical stimulus despite of aggravating factors.

Keywords

References

  1. Mustoe TA, O'Shaughnessy K, Kloeters O: Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. Plast Reconstr Surg 117: 35S, 2006
  2. Goldman R: Growth factors and chronic wound healing: past, present, and future. Adv Skin Wound Care 17: 24, 2004 https://doi.org/10.1097/00129334-200401000-00012
  3. Reid RR, Said HK, Mogford JE, Mustoe TA: The future of wound healing: pursuing surgical models in transgenic and knockout mice. J Am Coll Surg 199: 578, 2004 https://doi.org/10.1016/j.jamcollsurg.2004.05.262
  4. Myers SR, Partha VN, Soranzo C, Price RD, Navsaria HA: Hyalomatrix: a temporary epidermal barrier, hyaluronan delivery, and neodermis induction system for keratinocyte stem cell therapy. Tissue Eng 13: 2733, 2007 https://doi.org/10.1089/ten.2007.0109
  5. Gravante G, Delogu D, Giordan N, Morano G, Montone A, Esposito G: The use of hyalomatrix PA in the treatment of deep partial-thickness burns. J Burn Care Res 28: 269, 2007 https://doi.org/10.1097/BCR.0B013E318031A236
  6. Gravante G, Sorge R, Merone A, Tamisani AM, Di Lonardo A, Scalise A, Doneddu G, Melandri D, Stracuzzi G, Onesti MG, Cerulli P, Pinn R, Esposito G: Hyalomatrix PA in burn care practice: results from a national retrospective survey, 2005 to 2006. Ann Plast Surg 64: 69, 2010 https://doi.org/10.1097/SAP.0b013e31819b3d59
  7. Davidson JM, Nanney LB, Broadley KN, Whitsett JS, Aquino AM, Beccaro M, Rastrelli A: Hyaluronate derivatives and their application to wound healing: preliminary observations. Clin Mater 8: 171, 1991 https://doi.org/10.1016/0267-6605(91)90027-D
  8. Campoccia D, Hunt JA, Doherty PJ, Zhong SP, O'Regan M, Benedetti L, Williams DF: Quantitative assessment of the tissue response to films of hyaluronan derivatives. Biomaterials 17: 963, 1996 https://doi.org/10.1016/0142-9612(96)84670-9
  9. Costagliola M, Agrosi M: Second-degree burns: a comparative, multicenter, randomized trial of hyaluronic acid plus silver sulfadiazine vs. silver sulfadiazine alone. Curr Med Res Opin 21: 1235, 2005 https://doi.org/10.1185/030079905X56510
  10. West DC, Hampson IN, Arnold F, Kumar S: Angiogenesis induced by degradation products of hyaluronic acid. Science 228: 1324, 1985 https://doi.org/10.1126/science.2408340
  11. Rooney P, Wang M, Kumar P, Kumar S: Angiogenic oligosaccharides of hyaluronan enhance the production of collagens by endothelial cells. J Cell Sci 213: 105, 1993